Davis Alan K, Arterberry Brooke J, Xin Yitong, Agin-Liebes Gabrielle, Schwarting Corrine, Williams Monnica T
Center for Psychedelic Drug Research and Education, College of Social Work, The Ohio State University, Columbus, OH, United States.
Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University, Baltimore, MD, United States.
Front Epidemiol. 2022 Mar 23;2:876706. doi: 10.3389/fepid.2022.876706. eCollection 2022.
The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States.
Data came from the 2015-2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( = 41,060; female = 40.4%). Descriptive and multinomial logistic regression analyses were conducted in Stata.
Highest prevalence of past year hallucinogen use was among Asian females (35.06%), which was two-or-more times larger than prevalence of past year use among White males/females and Native American males. More than half of White males/females, Multiracial males, and Hispanic males reported had ever-used psilocybin or LSD, whereas less than one-quarter of Black males/females reported lifetime psilocybin use, and less than a third of Black females reported lifetime LSD use. Native American males had the lowest prevalence of lifetime MDMA use (17.62-33.30%) but had the highest lifetime prevalence of peyote use (40.37-53.24%). Pacific Islander males had the highest prevalence of lifetime mescaline use (28.27%), and lifetime DMT use was highest among Pacific Islander males/females (15.68-38.58%). Black, Asian, and Multiracial people had greater odds of past-year (ORs = 1.20-2.02; s < 0.05) and past-month (ORs = 1.39-2.06; s < 0.05) hallucinogen use compared to White people. Females had lower odds of past-year (OR = 0.79; s < 0.05), past-month (OR = 0.78; s < 0.05) hallucinogen use compared to males, except for lifetime use of MDMA (OR = 1.29; s < 0.05).
These findings should inform public health initiatives regarding potential benefits and risks of hallucinogen use among racial/ethnic groups and women.
本研究是首批调查美国终生使用致幻剂者中种族、族裔和性别在致幻剂使用流行率及趋势方面差异的研究之一。
数据来自2015 - 2019年全国药物使用和健康调查,包括报告曾使用过致幻剂的受访者(n = 41,060;女性占40.4%)。在Stata软件中进行描述性分析和多项逻辑回归分析。
过去一年致幻剂使用率最高的是亚洲女性(35.06%),这一比例是白人男性/女性以及美国原住民男性过去一年使用率的两倍或更高。超过一半的白人男性/女性、混血男性和西班牙裔男性报告曾使用过裸盖菇素或麦角酸二乙酰胺(LSD),而不到四分之一的黑人男性/女性报告终生使用过裸盖菇素,不到三分之一的黑人女性报告终生使用过LSD。美国原住民男性终生使用摇头丸(MDMA)的比例最低(17.62% - 33.30%),但使用仙人球毒碱的终生患病率最高(40.37% - 53.24%)。太平洋岛民男性终生使用三甲氧苯乙胺的患病率最高(28.27%),终生使用二甲基色胺(DMT)的比例在太平洋岛民男性/女性中最高(15.68% - 38.58%)。与白人相比,黑人、亚洲人和混血人群过去一年(比值比[ORs] = 1.20 - 2.02;P值 < 0.05)和过去一个月(ORs = 1.39 - 2.06;P值 < 0.05)使用致幻剂的几率更高。与男性相比,女性过去一年(OR = 0.79;P值 < 0.05)、过去一个月(OR = 0.78;P值 < 0.05)使用致幻剂的几率较低,但终生使用MDMA的情况除外(OR = 1.29;P值 < 0.05)。
这些发现应为有关种族/族裔群体及女性使用致幻剂的潜在益处和风险的公共卫生倡议提供参考。